Blood Cancer Journal最新文献

{"title":"Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma","authors":"Alice X. Wang, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Carlyn R. Tan, Issam S. Hamadeh, Ross S. Firestone, Eric Jurgens, Kevin Miller, Dhwani Patel, Neha Korde, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Hamza Hashmi, Sridevi Rajeeve, Urvi A. Shah, Kylee Maclachlan, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Saad Z. Usmani, Malin Hultcrantz","doi":"10.1038/s41408-026-01594-9","DOIUrl":"https://doi.org/10.1038/s41408-026-01594-9","url":null,"abstract":"Bispecific antibody (BsAb) treatment in multiple myeloma can be associated with adverse events including cytokine release syndrome (CRS), cytopenias, and infections. While granulocyte colony-stimulating factors (G-CSF) can be used to treat neutropenia, little is known about their safety during the BsAb initiation period and whether G-CSF can increase the risk of CRS. To assess the impact of G-CSF on risk of CRS, we included all patients with multiple myeloma who received at least one dose (step-up doses [SUD] and first treatment dose [FTD]), of commercial teclistamab, elranatamab, or talquetamab between November 2022 and April 2024 at Memorial Sloan Kettering Cancer Center (N = 186). Exposure to G-CSF was defined as administration of at least one dose of filgrastim from 48 h before up to 7 days after BsAb SUD or FTD, or one dose of peg-filgrastim between 7 days prior to up to 7 days after BsAb SUD or FTD. Of the 186 patients, 22 were classified as G-CSF exposed. CRS occurred in 16/22 (73%) patients with G-CSF exposure vs 76/164 (46%) of non-exposed. All CRS was grade 1 (56%) or grade 2 (44%) and the majority occurred prior to G-CSF was given (16/22 patients). The median absolute neutrophil count (ANC) at time of G-CSF exposure was 0.5 × 109/L (0.4–0.7). There was a trend towards increased risk of CRS after G-CSF exposure, although not significant (hazard ratio [HR] 1.7, 95% confidence interval [CI] 0.6–4.7, p = 0.3). These results suggest that G-CSF administration can be considered for neutropenia during BsAb initiation.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"2 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148693501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study.","authors":"Haley Thigpen, Kendall Diebold, Todd Mudd, Maris Hardee, Manuel Espinoza-Gutarra, Antonio Di Stasi, Donna Salzman, Razan Mohty, Jorge Cortes, Ravi Bhatia, Omer Jamy","doi":"10.1038/s41408-026-01601-z","DOIUrl":"10.1038/s41408-026-01601-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13448468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of adult acute lymphoblastic leukemia-a therapeutic revolution in the making.","authors":"Hagop Kantarjian, Ayalew Tefferi","doi":"10.1038/s41408-026-01583-y","DOIUrl":"10.1038/s41408-026-01583-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma","authors":"Lawrence Liu, Byron Sigel, Mei Wang, Nikhil Grandhi, Martin W. Schoen, Kristen M. Sanfilippo, Kenneth R. Carson, Murali Janakiram, Tzeyu L. Michaud, Graham A. Colditz, Theodore S. Thomas, Su-Hsin Chang","doi":"10.1038/s41408-026-01592-x","DOIUrl":"https://doi.org/10.1038/s41408-026-01592-x","url":null,"abstract":"Diabetes Mellitus (DM) is a risk factor for multiple myeloma (MM), but the relationship between diabetic control and risk of progression to MM in patients with monoclonal gammopathy of undetermined significant (MGUS) is unclear. We conducted a retrospective cohort study of US Veterans diagnosed with MGUS from 10/1/1999-12/31/2023 with prior DM. MGUS and MM diagnoses were confirmed using published natural language processing-assisted models. The exposure was time-varying glycated hemoglobin (HbA1c) > 7% during the follow-up (time of MGUS to MM, death, or being censored on 4/15/2025, whichever occurred first). The outcome was time from MGUS to MM. The association was estimated by multivariable-adjusted hazard ratio (aHR) using a Fine-Gray subdistribution hazard model with death as a competing event, adjusted by inverse probability of treatment weighting (IPTW). Among 11,061 patients with DM, HbA1c > 7% was associated with increased progression risk (aHR 1.15; 95% confidence interval [CI] 1.01–1.32). This association was stronger in the subgroups of Type-2 DM (T2DM) with insulin use (n = 7070; aHR 1.46; 95% CI 1.19–1.78) and non-use (n = 3724; aHR 1.42; 95% CI 1.14–1.77) throughout follow-up. For patients with T2DM and MGUS, poorly controlled diabetes may be associated with progression risk to MM. Future studies are needed to confirm this relationship.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"91 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148693479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine.","authors":"Ting Shi, Ruicong Xue, Jing Jia, Menghan Liu, Yalan Zhou, Chuanying Geng, Yuan Jian, Ying Tian, Yanru Zhang, Wenjing Li, Lefu Huang, Huixing Zhou, Aijun Liu, Wen Gao, Wenming Chen, Yun Leng, Yin Wu, Hong-Hu Zhu","doi":"10.1038/s41408-026-01588-7","DOIUrl":"10.1038/s41408-026-01588-7","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luvometinib in recurrent/refractory pediatric Langerhans cell histiocytosis: a single-arm, multi-center, phase 2 trial","authors":"Rui Zhang, Rong Liu, Jie Yu, Jianpei Fang, Ju Gao, Aiguo Liu, Sixi Liu, Wei Liu, Xuequn Luo, Yongmin Tang, Jian Ge, Xingli Wang, Zhuli Wu, Xin Huang, Zhen Wei, Yang Zheng","doi":"10.1038/s41408-026-01585-w","DOIUrl":"https://doi.org/10.1038/s41408-026-01585-w","url":null,"abstract":"Although mitogen-activated protein kinase pathway inhibitors have been approved for adult histiocytic neoplasms, none has been approved for pediatric Langerhans cell histiocytosis (LCH). This single-arm, open-label, phase 2 trial (NCT05997602) evaluated the efficacy and safety of luvometinib, a MEK1/2 inhibitor, in recurrent/refractory pediatric LCH, regardless of genotypes. Primary endpoint was independent review committee-assessed objective response rate (ORR) per positron emission tomography response criteria (PRC). Between September 21, 2023, and February 19, 2025, 46 patients were enrolled. The median follow-up was 15.1 months (range, 6.0–22.7). Among 42 patients in efficacy analysis set, the ORR and disease control rate assessed by IRC per PRC were 90.5% (95% CI, 77.4–97.3) and 95.2% (95% CI, 83.8–99.4), respectively. Based on Histiocyte Society Evaluations and Treatment guidelines, investigator-assessed ORR was 97.8% (95% CI, 88.5–99.9) and 12-month progression-free survival rate was 97.8% (95% CI, 85.6–99.7). Variant allele frequency of MAPK pathway mutations in cell-free DNA became undetectable in 78.9% (15/19) of patients. Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 4 (8.7%) patients. No TRAE led to treatment discontinuation. In the first prospective genotype-agnostic phase 2 study in pediatric LCH, luvometinib demonstrated profound response in the recurrent/refractory setting across diverse genotypes with an acceptable safety profile. Trial registration: This study was registered with ClinicalTrials.gov on August 8, 2023 (Identifier: NCT05997602).","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"40 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148612665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study.","authors":"Lei Ju, Sifeng Gao, JiLei Zhang, Yuyu Liu, Qiang Song, Lin Dong, Yan Guo, Xuemei Qin, Jie Zou, Chenglu Yuan, Yan Shi, Dexiao Kong, Kaifeng Wang, Qiang Li, Donglin Yang, Qingliang Teng, Erlie Jiang, Jun Peng, Guanchen Bai","doi":"10.1038/s41408-026-01589-6","DOIUrl":"10.1038/s41408-026-01589-6","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13415782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium","authors":"Aimaz Afrough, Oren Pasvolsky, Andrew J. Portuguese, Saurabh Zanwar, Mahmoud R. Gaballa, Aishwarya Sannareddy, Danai Dima, Utkarsh Goel, Hossam M. Ali, Kelley Julian, Andre De Menezes Silva Corraes, Murali Janakiram, Scott Goldsmith, James A. Davis, Kimberly Green, Noa Biran, Lindsay Fogel, Eli Zolotov, Megan M. Herr, Hamza Hassan, Leyla Shune, Jeries Kort, Christina Ye, Susan Bal, Luciano J. Costa, Laura Joiner, Samer AL Hadidi, Adeel M. Khan, Shahzad Raza, Faiz Anwer, Jack Khouri, Rahul Banerjee, Raffaela Cassano Cassano, Surbhi Sidana, Masooma Shifa Rana, Lekha Mikkilineni, Hitomi Hosoya, Shebli Atrash, Christopher Ferreri, Cindy Varga, Douglas W. Sborov, Shonali Midha, Omar Nadeem, Ariel Grajales-Cruz, Rachid Baz, Brandon Blue, Ciara Freeman, Frederick L. Locke, Krina K. Patel, Yi Lin, Shaji K. Kumar","doi":"10.1038/s41408-026-01565-0","DOIUrl":"https://doi.org/10.1038/s41408-026-01565-0","url":null,"abstract":"Talquetamab, a GPRC5D-targeting bispecific antibody, shows promising activity in relapsed-refractory multiple myeloma. However, real-world outcomes in patients with extramedullary disease (EMD) remain poorly described. We studied 360 patients treated with talquetamab at 15 U.S. centers by Dec 2024. Soft tissue plasmacytomas (STP) were classified as EMD (not contiguous with bone) or paraskeletal disease (PSD; contiguous with bone). If both were present, patients were assigned to the EMD category. Of those, 97 (27%) had EMD, 22 (6%) had PSD, and 241 (67%) had No-STP. Median follow-up was 12.8 months. Overall response rates were 68% in EMD, 63% in PSD, and 65% in No-STP (p = 0.8). Median progression-free survival was 4.3, 4.5, and 7.8 months, respectively (p = 0.009), and median overall survival was 10.3 months, 13.0 months, and not reached (p = 0.070). These findings demonstrate that EMD and PSD are associated with preserved response rates but shorter PFS and OS with talquetamab. While systemic markers of tumor burden and inflammation—particularly lactate dehydrogenase (LDH) and ferritin—emerged as independent predictors of inferior PFS, elevated LDH also retained independent prognostic significance for OS. While EMD was associated with shorter PFS and OS on univariate analysis, it did not retain independent prognostic significance on multivariable analysis, suggesting that inferior outcomes are driven by aggressive disease biology rather than by lesion anatomy alone. These findings are hypothesis-generating and require prospective validation. Talquetamab retains clinical utility in this high-risk population with EMD, though outcomes are suboptimal with a need for further refinement of treatment approaches.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148612669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes.","authors":"Masataka Sakashita, Junya Kanda, Keiichiro Hattori, Nobuhiro Hiramoto, Nobuhiro Kanemura, Senji Kasahara, Mitsumasa Watanabe, Satoshi Yoshihara, Michiko Ichii, Nobuo Sezaki, Masaaki Tsuji, Takeshi Maeda, Ko Sasaki, Toshiyuki Kitano, Yasuko Miyahara, Tadakazu Kondo, Mamiko Sakata-Yanagimoto, Akifumi Takaori-Kondo, Seishi Ogawa, Yasuhito Nannya","doi":"10.1038/s41408-026-01586-9","DOIUrl":"10.1038/s41408-026-01586-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.","authors":"Chenying Li, Hongyan Tong, Huafeng Wang, Yanling Ren, Jiejing Qian, Xinping Zhou, Gaixiang Xu, Liangshun You, Liping Mao, Haitao Meng, Wenjuan Yu, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Wanzhuo Xie, Jie Jin, Yinjun Lou","doi":"10.1038/s41408-026-01591-y","DOIUrl":"10.1038/s41408-026-01591-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13408405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148598966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}